Effective oncolytic vaccinia therapy for human sarcomas Academic Article uri icon

Overview

MeSH Major

  • Bone Neoplasms
  • Cancer Vaccines
  • Oncolytic Virotherapy
  • Sarcoma
  • Soft Tissue Neoplasms
  • Vaccinia virus

abstract

  • GLV-1h68 has potent direct oncolytic effects against human sarcoma in┬ávitro and in┬ávivo. Recombinant vaccinia oncolytic virotherapy could provide a new platform for the treatment of patients with bone and soft tissue sarcomas. Future clinical trials investigating oncolytic vaccinia as a therapy for sarcomas are warranted.

publication date

  • June 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3350611

Digital Object Identifier (DOI)

  • 10.1016/j.jss.2011.11.1030

PubMed ID

  • 22341347

Additional Document Info

start page

  • e53

end page

  • 60

volume

  • 175

number

  • 2